Trial intelligence / Profile preview

PF-06835919 in Hereditary Fructose Intolerance

NCT06089265Phase 2

Key facts

Status: Completed
Start: Jun 2023
Primary completion: Nov 2023
Countries: 1
Sponsor: Maastricht University Medical Center+
Modality: Small Molecules

Drugs: PF-06835919
Conditions: hereditary fructose intolerance (HFI)

Overview

Phase 2, open-label trial of PF-06835919 in hereditary fructose intolerance (HFI) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Intestinal Fructose Tolerance at 9 days, Renal Fructose Tolerance at 9 days and 1 more. Started Jun 2023; status: completed.

Design

2 arms

Study design: Non-randomizedOpen-label

HFI patients
HFI participants receive PF-06835919 for 9 days followed by challenge.
Healthy controls
Healthy controls receive no intervention, only fructose tolerance test.

Endpoints

Primary

Intestinal Fructose Tolerance9 days
Renal Fructose Tolerance9 days
Hepatic Fructose Tolerance9 days

Secondary

Intrahepatic Lipid Content9 days
Blood Pressure9 days
Glycosylated Transferrin9 days

Beyond the preview

Go deeper on NCT06089265.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT06089265.